Tesamorelin Research Hub — Stabilised GHRH Analog Studies
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone releasing hormone (GHRH) with a stabilising trans-3-hexenoyl modification at the N-terminus. It is one of the most thoroughly characterised GHRH analogues in the clinical literature, particularly for studies of visceral adipose tissue and the GH/IGF-1 axis.
What this hub covers
- Stabilised GHRH(1-44) structure and DPP-IV resistance
- Pulsatile GH release vs exogenous somatropin
- Downstream IGF-1 induction kinetics
- Comparisons to sermorelin, CJC-1295 (DAC/no-DAC) and ipamorelin
- Research models of visceral adipose tissue and lipid metabolism
Tesamorelin research articles
All research →Tesamorelin Research Overview
A synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), studied for its role in GH/IGF-1 axis stimulation, visceral adiposity reduction, and metabolic research contexts.
Read article →Tesamorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for tesamorelin — the GHRH(1-44) analog with the strongest clinical evidence base for visceral-fat reduction.
Read article →Sermorelin Research Overview
Sermorelin (GHRH 1–29 NH₂) is a synthetic 29-amino acid analogue of the N-terminal active fragment of endogenous growth hormone-releasing hormone — the foundational GHRH-based research compound that established the pituitary-stimulating approach to GH axis restoration and preceded all subsequent GHRH analogues including Tesamorelin and Modified GRF 1-29.
Read article →Sermorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for sermorelin — the GHRH(1-29) reference peptide and closest pharmacologic proxy to physiologic GH pulses.
Read article →CJC-1295 DAC vs No DAC: Research Overview
A research-context comparison of CJC-1295 with and without the Drug Affinity Complex modification — pharmacokinetics, GH secretion patterns, and the implications for pulsatility.
Read article →HGH vs Peptide-Based GH Stimulation: A Research Comparison
A definitive research comparison of exogenous HGH (somatropin) versus peptide-based GH axis stimulation using GHRH analogues and GHRPs — covering pulsatility, physiological authenticity, IGF-1 profiles, receptor sensitivity, regulatory status, cost, and how to select the right approach for specific research applications.
Read article →Tesamorelin research FAQ
- How does tesamorelin differ from native GHRH?
- Tesamorelin carries a trans-3-hexenoyl group at the N-terminal tyrosine, which dramatically slows cleavage by dipeptidyl peptidase IV (DPP-IV). This extends plasma half-life and preserves the receptor-activating sequence, producing a more sustained pituitary GH response than native GHRH(1-44).
- How does tesamorelin compare to CJC-1295?
- Both are stabilised GHRH analogues, but CJC-1295 with DAC adds a drug-affinity complex that binds serum albumin and extends half-life to days, while tesamorelin and CJC-1295 (no-DAC) act on shorter timescales that preserve pulsatility. The CJC-1295 DAC vs no-DAC overview details the trade-offs.
- Why is tesamorelin studied alongside HGH?
- Tesamorelin stimulates endogenous pulsatile GH release, while exogenous HGH supplies somatropin directly. Researchers compare the two to study physiological authenticity, IGF-1 induction patterns and downstream body-composition endpoints. See the HGH vs Peptide GH Stimulation comparison for the full breakdown.
- What downstream markers do tesamorelin studies track?
- Most published research tracks serum GH, IGF-1 and IGFBP-3 as primary endocrine endpoints, with secondary measures around lipid handling and visceral adipose tissue depending on the model.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.